Z15.09 Insurance Policy Changes

ICD-10 Z15.09 is officially defined as "Genetic susceptibility to other malignant neoplasm." code Z15.09 is referenced in 4 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z15.09 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2026Medium impact
Genetic Testing for Li-Fraumeni Syndrome
Genetic testing for TP53 may be considered medically necessary to confirm Li-Fraumeni syndrome in individuals who meet the classic or Chompret clinical diagnostic criteria, in individuals with early-onset breast cancer (age of diagnosis under 31 years), or in pediatric hypodiploid acute lymphoblastic leukemia. Targeted TP53 familial variant testing may be considered medically necessary in an at-risk relative of a proband with a known TP53 pathogenic variant, and genetic testing for a germline TP53 variant is investigational for all other indications. Effective 2026-10-01, the code reference was updated to remove an ICD-9 diagnosis code and add ICD-10 diagnosis codes QA1.790, QA1.791 and QA1.792.
Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2026Medium impact
Germline Genetic Testing for Hereditary Diffuse Gastric Cancer (CDH1, CTNNA1)
Germline CDH1 testing for hereditary diffuse gastric cancer may be considered medically necessary when individuals meet listed criteria, such as a diagnosis of diffuse gastric cancer before age 50, a diagnosis of diffuse gastric cancer at any age in individuals of Maori ethnicity or with a personal or family history of cleft lip/palate, or a diagnosis of bilateral lobular breast cancer before age 70. CDH1 testing for individuals who do not meet these criteria, and CTNNA1 testing, are considered investigational. The code reference section was updated on 10/01/2026 to add ICD-10 diagnosis code QA1.71.
Aetna · Identified Aug 19, 2026Medium impact
Magnetic Resonance Imaging (MRI) of the Breast (CPB 0105, reviewed 2026-08-06)
Aetna considers breast MRI medically necessary for members who had a recent (within the past year) conventional mammogram and/or breast sonogram, when MRI may affect clinical management. Covered circumstances include detecting local tumor recurrence after mastectomy and breast reconstruction with an implant, assessing residual cancer after an incomplete lumpectomy, and adjunct screening to mammography for women at high genetic risk or with a lifetime breast cancer risk of 20 to 25 percent or more. Breast MRI is considered experimental, investigational or unproven for listed uses such as screening women with average breast cancer risk, evaluating BI-RADS 4 or 5 lesions found on mammogram or ultrasound, and screening women with dense breasts who are asymptomatic and have no additional risk factors. Computer-aided detection is considered integral to breast MRI and is not separately reimbursed.
Aetna · Identified Aug 17, 2026Medium impact
Genetic Counseling (CPB 0189, reviewed 2026-03-27)
Aetna considers genetic counseling medically necessary for listed pregnancy-related indications, including couples who are closely related genetically, familial cancer disorders, pregnant women with maternal age 35 years or greater at delivery, and parents of a child born with a genetic disorder or birth defect. Genetic counseling unrelated to pregnancy is covered when it is appropriate for, or provided with, medically necessary genetic testing in accordance with ACMG guidelines. Genetic counseling for all other indications is considered experimental, investigational or unproven.

Watch Z15.09

Get one email when a payer policy names Z15.09, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z15.09?

There are 4 tracked policy changes affecting code Z15.09, including updates from Blue Cross & Blue Shield of Mississippi, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z15.09?

Payers that have issued tracked updates for code Z15.09 include: Blue Cross & Blue Shield of Mississippi, Aetna.

How do I get notified when code Z15.09 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z15.09. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z15.09?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Genetic Testing for Li-Fraumeni Syndrome

Germline Genetic Testing for Hereditary Diffuse Gastric Cancer (CDH1, CTNNA1)

Magnetic Resonance Imaging (MRI) of the Breast (CPB 0105, reviewed 2026-08-06)

Genetic Counseling (CPB 0189, reviewed 2026-03-27)

What insurance policy changes affect code Z15.09?

Which payers have updated policy for code Z15.09?

How do I get notified when code Z15.09 policy changes?

Why do payers change policies for code Z15.09?